Home
Storia in 3 fonti
Alzheimer’s drugs ‘make no meaningful difference to patients’, major study claims
Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK
- ·
theguardian.com
Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes
Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline
- ·
bbc.com
'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests
A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.
- ·
independent.co.uk
Alzheimer’s drugs ‘make no meaningful difference to patients’, major study claims
Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK